ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines ...
Stockhead on MSN
Alterity in spotlight at medical conferences as MSA clinical research moves toward Phase III planning
Presentations at key medical conferences in May support advancement of Alterity’s lead drug ATH434 into Phase III development for Multiple ... Read More The post Alterity in spotlight at medical ...
SynuSight Biotech (SynuSight), a clinical-stage biotech company focused on innovative pipeline development for neurodegenerative diseases, today announced the publication of a collaborative study in ...
Prof. Hilal A. Lashuel, professor of neuroscience in neurology at Weill Cornell Medicine-Qatar (WCM-Q) – a Qatar Foundation ...
Alzheimer’s doesn’t begin with memory loss. It starts decades earlier. New research reveals that a simple trace mineral may ...
Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of ...
Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global investors. Proceeds are expected to fund the Company through ...
Morning Overview on MSN
A new laser treatment just beat back dry macular degeneration in an Aalto trial — gently heating the retina to save the vision of millions sliding toward blindness
Somewhere around 200 million people worldwide live with age-related macular degeneration, and for those with the dry form of ...
Qatar Tribune on MSN
Int’l team led by WCM-Q professor awarded $9mn Parkinson’s research grant
Tribune News NetworkDoha Prof. Hilal A. Lashuel, professor of neuroscience in neurology at Weill Cornell Medicine-Qatar (WCM-Q), a Qatar Foundation partner university, has been awarded a $9 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results